ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 844

Impact of Glucocorticoid Tapering on Markers of Bone Metabolism in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab: Exploratory Analysis from a Randomized Controlled Trial

Frank Buttgereit1, Gerd Burmester 2, J. Michael Nebesky 3, Jenny Devenport 3, Marc Y. Donath 4 and Markus R. John 3, 1Charité-Universitätsmedizin Berlin, Berlin, Germany, 2Charité—University Medicine Berlin, Berlin, Germany, 3F. Hoffmann-La Roche, Basel, Switzerland, 4University Hospital Basel, Basel, Switzerland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: glucocorticoids and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S078: RA – Diagnosis, Manifestations, & Outcomes I: Pulmonary & Other Comorbidities (839–844)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Glucocorticoids (GCs) directly impact bone metabolism via increased bone resorption and inhibited bone formation1; hence, systemic fracture risk increases with daily and cumulative GC doses.2 However, many patients with established rheumatoid arthritis (RA) receive long-term treatment with GCs to suppress inflammation, which confers some benefit in delaying bone erosion.3 This exploratory analysis of the SEMIRA (Steroid EliMination In RA) study4 compared changes in markers of bone and cartilage metabolism in RA with low disease activity (LDA) or remission on tocilizumab (TCZ) + GC ± conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) who received either slow GC tapering (GC-taper) or continuation (5 mg; GC-5mg).

Methods: Patients (diagnosed per revised 1987 ACR criteria) had at least stable LDA (DAS28-ESR ≤3.2) for ≥4 weeks, were receiving a stable prednisone regimen (5 mg/day) + TCZ ± csDMARDs for ≥4 weeks, and received TCZ + GCs (prednisone equivalent 5-15 mg/day) for ≥6 months before randomization. Patients were randomly assigned to GC-5mg (n=128) or GC-taper (n=131; starting at 4 mg/day with 1-mg reduction every 4 weeks to 0 mg/day at weeks 16-24) for 24 weeks, during which TCZ ± csDMARDs remained stable. Change between baseline (BL) and week 24 in serum levels of markers of bone and cartilage metabolism—including N-terminal propeptide of type 1 collagen (P1NP), C-terminal telopeptide of type 1 collagen (CTX1), alkaline phosphatase (ALP), matrix metalloproteinase 3 (MMP3), calcium, phosphorus, and albumin—were exploratory outcomes. Within-group and between-group changes from baseline were evaluated by Wilcoxon paired rank test and Wilcoxon signed rank test, respectively.

Results: Figure 1 shows changes from BL to week 24 in bone and cartilage biomarkers. MMP3 (marker of cartilage degradation) was reduced at week 24 in the GC-taper group compared with GC-5mg. Change from BL at week 24 in P1NP (bone formation) and CTX1 (bone resorption) favored the GC-taper arm, with P1NP increasing relatively more than CTX1 (44% and 24%, respectively, compared with GC-5mg), indicating net anabolism. The increase in ALP from BL to week 24 was greater for the GC-taper arm than for the GC-5mg arm, suggesting neomineralization. There was no difference in the change from BL to week 24 in calcium, phosphorus, or albumin (not shown).

Conclusion: The findings of this biochemical marker analysis suggest that withdrawal from GC after achievement of LDA or remission with TCZ results in increased bone remodeling, with a trend toward an anabolic window and reduced cartilage degradation. Given that it could take a year to recover from increased fracture risk after cessation of GC therapy,5 our results offer further insight on the reversible risk of systemic harm to noninflamed bone versus benefits for inflamed joints in the context of LDA or remission.

References: 1. Canalis E, Delany AM. Ann N Y Acad Sci 2002;966:73. 2. Van Staa TP et al. Rheumatology 2000;39:1383. 3. Kavanaugh A, Wells AF. Rheumatology 2014;53:1742. 4. Burmester GR et al. Arthritis Rheumatol 2018;70(suppl 10). 5. Vestergaard P et al. Calcif Tissue Int 2008;82:249.


Disclosure: F. Buttgereit, Medac, 2, 5, 8, Pfizer, 2, 5, 8, Roche, 5, Roche/Chugai, 2, 5, 8, Roche-Chugai, 2, 5, 8, Sanofi-Genzyme, 2, 5, 8; G. Burmester, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma., 5, 8, AbbVie Inc., 5, 8, BMS, 5, 8, Eli Lilly, 5, 8, Eli Lilly and Company, 5, Gilead, 5, 8, Gilead Sciences, Inc., 5, 8, Janssen, 5, 8, Lilly, 5, 8, Merck, 5, 8, Merck Shar & Dohme, 5, 8, MSD, 5, 8, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Roche, Sanofi-Genzyme, 5, 8, Sanofi, 5, 8, UCB, 5, 8, Union Chimique Belge, 2, 5, 8; J. Nebesky, F. Hoffmann La-Roche, Inc., 3, 4; J. Devenport, Genentech, 3; M. Donath, Roche, 5, Roche, MSD, NovoNordisk, Lilly, Boehringer Ingelheim, AstraZeneca, 5; M. John, Roche, 3, 4.

To cite this abstract in AMA style:

Buttgereit F, Burmester G, Nebesky J, Devenport J, Donath M, John M. Impact of Glucocorticoid Tapering on Markers of Bone Metabolism in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab: Exploratory Analysis from a Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/impact-of-glucocorticoid-tapering-on-markers-of-bone-metabolism-in-patients-with-rheumatoid-arthritis-who-achieved-low-disease-activity-or-remission-on-tocilizumab-exploratory-analysis-from-a-randomi/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-glucocorticoid-tapering-on-markers-of-bone-metabolism-in-patients-with-rheumatoid-arthritis-who-achieved-low-disease-activity-or-remission-on-tocilizumab-exploratory-analysis-from-a-randomi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology